Literature DB >> 31931540

Management of hepatic encephalopathy in Germany: a survey among physicians.

Christian Labenz1, Charles C Adarkwah2,3, Marcus-Alexander Wörns1, Stephan Miehlke4, Wolf P Hofmann5, Peter Buggisch6, Peter R Galle1, Thomas Frieling7, Joachim Labenz8.   

Abstract

BACKGROUND: Hepatic encephalopathy (HE) is a severe complication of liver cirrhosis with impairment of quality of life and prognosis. Management patterns among physicians have not been investigated yet.
METHODS: A questionnaire containing 17 questions was sent out to 1468 gastroenterologists and 120 general practitioners (GPs). It included questions regarding diagnostic, therapeutic, and management strategies used in patients with overt HE (OHE) and covert HE (CHE).
RESULTS: The response rate was 12 % (n = 172) for gastroenterologists and 45 % (n = 54) for GPs. Of gastroenterologists, 26.7 % examine patients with an initial diagnosis of liver cirrhosis regarding HE. Gastroenterologists favored a combination of different testing strategies (27.9 %) and clinical examination (23.0 %), while the biggest part of the GPs use clinical examination (55.3 %); 63.7 % of gastroenterologists and 28.3 % of GPs give correct nutritional advices to patients with HE. Treatment strategies for acute bouts of OHE and secondary prophylaxis varied widely in both groups. Preferred medication was lactulose followed by rifaximin or a combination therapy. More than half of the GPs (53.7 %) were not familiar with minimal HE (MHE). About one-third of both groups never tried to diagnose MHE.
CONCLUSION: Our data strongly indicate that management of HE is very heterogeneous among gastroenterologists as well as selected GPs working in Germany and not driven by evidence-based international guidelines. Thus, the national guideline is more than welcome. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31931540     DOI: 10.1055/a-1010-6974

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  4 in total

1.  Minimal Hepatic Encephalopathy and Biejia-Ruangan Are Associated with First Hospital Readmission in Nonalcoholic Cirrhosis Patients.

Authors:  Ting-Ting Jiang; Xiao-Li Liu; Yu-Yong Jiang; Xian-Bo Wang; Zhi-Yun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-07       Impact factor: 2.629

2.  Evaluation of IL-6 for Stepwise Diagnosis of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis.

Authors:  Simon Johannes Gairing; Julian Anders; Leonard Kaps; Michael Nagel; Maurice Michel; Wolfgang Maximilian Kremer; Max Hilscher; Peter Robert Galle; Jörn M Schattenberg; Marcus-Alexander Wörns; Christian Labenz
Journal:  Hepatol Commun       Date:  2022-01-14

3.  Validation of a Simple Quality-of-Life Score for Identification of Minimal and Prediction of Overt Hepatic Encephalopathy.

Authors:  Mette Munk Lauridsen; Peter Jepsen; Charlotte Wilhelmina Wernberg; Ove B Schaffalitzky de Muckadell; Jasmohan S Bajaj; Hendrik Vilstrup
Journal:  Hepatol Commun       Date:  2020-07-03

4.  Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome.

Authors:  Xiao Yu; Ye Jin; Wangxiao Zhou; Tingting Xiao; Zhongwen Wu; Junwei Su; Hainv Gao; Ping Shen; Beiwen Zheng; Qixia Luo; Lanjuan Li; Yonghong Xiao
Journal:  Front Cell Infect Microbiol       Date:  2022-01-18       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.